Common psychotropic meds disrupt cholesterol synthesis in brain
We are all aware of the risks of elevated cholesterol in cardiovascular health, but it is also a lipid we can’t live without. Our bodies require cholesterol to form cell membranes, steroid hormones and vitamin D. And the brain contains around 20% to 25% of the body’s cholesterol, which it needs to develop and function. So what happens when cholesterol synthesis in our brains is disrupted?
Károly Mirnics, a professor at the University of Nebraska Medical Center, and his lab have long studied the molecular basis of brain disorders. Their recent paper on psychotropic medications that inhibit cholesterol biosynthesis in the brain has been published in the Journal of Lipid Research.
“Cholesterol is synthesized by a cascade of events that are complex and with multiple branches, but there is one particular molecule that is the direct precursor of cholesterol called 7-dehydrocholesterol, or 7-DHC,” Mirnics said. “7-DHC is very unstable, falls apart very quickly, and is the most oxidizable lipid known to mankind.”
An enzyme converts 7-DHC to cholesterol in the final step of the cholesterol biosynthesis pathway. In humans, the DHCR7 gene provides instruction to produce this enzyme, and mutations in this gene can cause Smith–Lemli–Opitz syndrome, or SLOS. Symptoms of this rare disorder, including growth and developmental delays, appear before or soon after birth. Elevated 7-DHC is a common molecular marker for diagnosis of SLOS.
“Around 10 years ago, several adult patients receiving commonly used psychotropic medications were misdiagnosed with SLOS based on their high 7-DHC levels,” Mirnics said. “These patients did not have a mutation in the (DHCR7) gene, so we asked if it could be from the medications, and that started our research.”
Aripiprazole, or ARI, an antipsychotic used to treat schizophrenia and bipolar disorder, and trazodone, or TRZ, an antidepressant, are commonly prescribed in the US. Psychiatrists often treat patients simultaneously with multiple drugs, but the side effects of these medications are not entirely known. So Mirnics and his group set out to investigate how they affect molecular and biochemical functions in the brain.
“I have to stress that our studies are all in mouse models, but the mouse cholesterol biosynthesis pathway is conserved across vertebrates, including humans,” Mirnics said.
When the researchers treated cell cultures and genetically modified mice with ARI and TRZ, they saw that the combined therapy disrupted cholesterol biosynthesis in developing brain cells such as neurons and astrocytes. Adult mice treated with ARI and TRZ had elevated levels of 7-DHC — just like the patients who were misdiagnosed with SLOS.
SLOS is very rare. Babies with the disorder must inherit two nonfunctional or mutated copies of the DHCR7 gene from each parent. Many more people, around 1% to 3% of the population, are asymptomatic carriers with one mutated and one functional copy of the gene. Mirnics cautions that individuals with genetic mutations in the cholesterol biosynthesis pathway are most vulnerable to treatment with medications like ARI and TRZ.
“I am not saying these drugs are bad,” Mirnics said. “But they may not be the best choice for individuals with genetic predisposition, or during pregnancy without knowing the genotype of the parents or the baby.”
The lab is trying to catalog all commonly used medications that disrupt cholesterol biosynthesis. Mirnics expects this information will be useful for physicians, especially when prescribing drugs for patients with genetic predispositions. In the near future, personalized medicine will exist in which our genetics could determine our drugs.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Opinions
Opinions highlights or most popular articles
I am not a fake. I am authentically me
Camellia Moses Okpodu explains why she believes the term “imposter syndrome” is inaccurate and should be replaced.
Where do we search for the fundamental stuff of life?
Recent books by Thomas Cech and Sara Imari Walker offer two perspectives on where to look for the basic properties that define living things.
Scientists around the world report millions of new discoveries every year
Science is a collaborative endeavor, and international teams have contributed to a huge rise in scientific output.
Who decides when a grad student graduates?
Ph.D. programs often don’t have a set timeline. Students continue with their research until their thesis is done, which is where variability comes into play.
Redefining ‘what’s possible’ at the annual meeting
The ASBMB Annual Meeting is “a high-impact event — a worthwhile investment for all who are dedicated to advancing the field of biochemistry and molecular biology and their careers.”
Molecular impressions of water as cuneiform cascade*
Inspired by "the most elegant depiction of H2O’s colligative features," Thomas Gorrell created a seven-tiered visual cascade of Sumerian characters beginning with the ancient sign for water.